Xtant Medical (NYSEAMERICAN:XTNT) Issues Earnings Results, Misses Estimates By $0.05 EPS

Xtant Medical (NYSEAMERICAN:XTNT) released its quarterly earnings data on Tuesday. The medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05), FiscalAI reports. The company had revenue of $23.03 million for the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Xtant Medical Trading Up 0.4%

NYSEAMERICAN XTNT opened at $0.45 on Tuesday. The company has a market cap of $62.56 million, a price-to-earnings ratio of 44.64 and a beta of -0.13. Xtant Medical has a 52 week low of $0.39 and a 52 week high of $0.95. The business has a 50 day moving average price of $0.44 and a 200-day moving average price of $0.51. The company has a quick ratio of 1.64, a current ratio of 3.34 and a debt-to-equity ratio of 0.17.

Institutional Trading of Xtant Medical

Several hedge funds have recently bought and sold shares of XTNT. Jane Street Group LLC acquired a new stake in Xtant Medical in the 2nd quarter valued at $26,000. Wiregrass Investment Management LLC acquired a new position in Xtant Medical during the fourth quarter worth $81,000. Mink Brook Asset Management LLC lifted its stake in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after buying an additional 205,945 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares during the last quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BTIG Research restated a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $1.00.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.